Mark Lappe, Founder

Chief Executive Officer

Mark founded Inhibrx with Brendan Eckelman and Quinn Deveraux in 2010 and served as the Chief Executive Officer since the company’s inception. Mark has extensive expertise in the biotechnology industry with over twenty years of experience in investment management and building the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mark was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.